Novartis invests in bispecifics for cancer; Bob Langer steps down from Moderna board
Summary
The departure of Kapur, who was appointed commercial head in late 2019, is notable as Geron just won U.S. approval of its first drug, Rytelo for myelodysplastic syndromes. Ned PagliaruloProlific researcher and biotechnology entrepreneur Robert Langer is stepping down from the board of directors of Moderna, a company he helped found in 2010. Another Moderna director, Stephen Berenson, has also stepped down and will be replaced by David Rubenstein, the co-founder and co-chairman of investment firm The Carlyle Group. Biovectra makes the active ingredients in pharmaceuticals and assists in other elements of production like fill-finish services, lipid nanoparticle formulation and large-scale commercial manufacturing. Agilent, which offers laboratory services to drugmakers, said the deal will help build its CDMO business and bring in expertise in fast-growing segments such as antibody drug conjugates and GLP-1 medicines.